<DOC>
	<DOCNO>NCT02540811</DOCNO>
	<brief_summary>The safety performance dCELL® ACL Scaffold evaluate 40 patient implanted investigational product follow ruptured anterior cruciate ligament ( ACL ) knee .</brief_summary>
	<brief_title>Clinical Evaluation dCELL® ACL Scaffold Reconstruction Anterior Cruciate Ligament</brief_title>
	<detailed_description>The dCELL® ACL Scaffold novel device manufacture porcine tissue use patented variation Tissue Regenix 's platform technology render tissue biocompatible free cellular material , provide biological scaffold safe human implantation whilst preserve biomechanical property . The device use reconstruct traumatic ACL tear help restore normal knee function therefore prevent wear cartilage future damage .</detailed_description>
	<mesh_term>Knee Injuries</mesh_term>
	<criteria>Patients partial complete tear ACL require reconstruction ACL . Medial Collateral Ligament ( MCL ) injury grade 2 less . Osteoarthritis grade 2 less Kellgren Lawrence scale . Patients give write informed consent ; willing able comply entire study procedure include rehabilitation protocol . Body Mass Index ( BMI ) great 35 kg/m2 . Treatment investigational drug device within two month prior screen . Patients present abnormal degenerative osteoarthritis joint . Previous ACL reconstruction target knee . Current ACL injury contralateral knee . Patients use anticoagulant within 2 week prior surgery . Patients current immunosuppressive radiation therapy within six month screen . Patients diabetes cardiovascular disease precludes elective surgery . Patients document renal disease metabolic bone disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>